Candid No. 1 Argentine Hemorrhagic Fever Vaccine Protects against Lethal Junin Virus Challenge in Rhesus Macaques

The protective efficacy of Candid No.1, a live-attenuated vaccine against Argentine hemorrhagic fever (AHF), was evaluated in non-human primates. Twenty rhesus macaques immunized 3 months previously with graded doses of Candid No. 1( 16 -127, 000 PFU), as well as 4 placebo-inoculated controls, were...

Full description

Saved in:
Bibliographic Details
Main Authors: McKee, Kelly T , Jr, Barrera Oro, Julio G, Kuehne, Anna I, Spisso, Joan A, Mahlandt, B G
Format: Report
Language:English
Subjects:
AHF(ARGENTINE HEMORRHAGIC FEVER)
ARGENTINA
ARGENTINA HEMORRHAGIC FEVER VACCINE
ATTENUATION
CANDID NO.1
CHALLENGES
FLUORESCENT ANTIBODY TECHNIQUES
HEMORRHAGIC FEVERS
IMMUNITY
IMMUNIZATION
IMMUNOFLUORESCENT ANTIBODY
JUNIN VIRUS
LABORATORY ANIMALS
LETHALITY
LIVE VACCINES
MACAQUE MONKEYS
Medicine and Medical Research
PRIMATES
PROTECTION
REPRINTS
RHESUS MONKEYS
VIREMIA
VIRUSES
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The protective efficacy of Candid No.1, a live-attenuated vaccine against Argentine hemorrhagic fever (AHF), was evaluated in non-human primates. Twenty rhesus macaques immunized 3 months previously with graded doses of Candid No. 1( 16 -127, 000 PFU), as well as 4 placebo-inoculated controls, were challenged with 4.41 log10 PFU of virulent P3790 strain Junin virus. All controls developed severe clinical disease; 3 of 4 died. In contrast, all vaccinated animals were fully protected; none developed any signs of AHF during a 105-day follow-up period. Viremia and virus shedding were readily detected in all placebo-vaccinated controls, while virus could be recovered only once (by amplification) from throat swabs of 2 Candid No 1 vaccinees on day 21.